2. UroToday Home
  3. Video Lectures

Advanced Prostate Cancer Videos

CDK12 Loss Drives Prostate Cancer Progression and Creates Therapeutic Vulnerability - Jean Tien
April 7, 2025
Details
PSMA Positive Extracellular Vesicles as Biomarkers in Oligometastatic Prostate Cancer - Jack Andrews
April 5, 2025
Details
ONECUT2 Crystal Structure Reveals Potential for Targeted Prostate Cancer Therapy - Brad Gallent
April 4, 2025
Details
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes - Marina Sharifi
April 3, 2025
Details
Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami
April 1, 2025
Details
Improving PSA Doubling Time Calculation for High Risk Biochemical Recurrence - Alicia Morgans
March 31, 2025
Details
Prognostic Value of ctDNA Fraction in Metastatic Castration-Resistant Prostate Cancer - Alessio Crippa
March 29, 2025
Details
PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente
March 27, 2025
Details
PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients - Hannah McManus
March 26, 2025
Details
Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami
March 25, 2025
Details
SPP1 Macrophages and Immunotherapy Resistance in Advanced Prostate Cancer - Aram Lyu
March 25, 2025
Details
PSA Responses with Darolutamide Plus ADT in the ARANOTE Trial - Fred Saad
March 24, 2025
Details
ARASENS Trial Analysis Investigates Impact of Initial PSA Values on Treatment Response in mHSPC - Alicia Morgans
March 23, 2025
Details
Bone-Protective Agents and Survival Benefits in PEACE-3 Trial Subgroup Analysis - Fred Saad
March 23, 2025
Details
Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario
March 21, 2025
Details
TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce
March 20, 2025
Details
LIBERTAS Clinical Trial Explores Treatment Optimization in mHSPC - Arun Azad
March 20, 2025
Details
Investigating PARP Expression as Biomarker for Targeted Therapy in Prostate Cancer - Emmanuel Antonarakis
March 20, 2025
Details
Examining Post-Prostatectomy Metastasis Patterns in Hormone-Sensitive Prostate Cancer - Nicolas Sayegh
March 19, 2025
Details
Comparing ARPI Options Across Disease Volume and Metastatic Timing in mHSPC - Syed Arsalan Ahmed Naqvi & Irbaz Riaz
March 19, 2025
Details
PERSIAN Trial Explores SBRT Benefits in Oligometastatic Hormone-Sensitive Prostate Cancer - Giulio Francolini
March 18, 2025
Details
Talazoparib and Enzalutamide in Unselected mCRPC Patients - Neeraj Agarwal
March 18, 2025
Details
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
March 17, 2025
Details
Targeting Lineage Plasticity in Prostate Cancer with EZH2 Inhibitor Mevrometostat - Michael Schweizer
March 17, 2025
Details
Systematic Review of Real-World Outcomes of Radium-223 in mCRPC Treatment - Rana McKay
March 17, 2025
Details
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett
March 16, 2025
Details
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
March 12, 2025
Details
EMBARK Trial Subanalysis for High-Risk Biochemical Recurrent Prostate Cancer - Stephen Freedland
March 10, 2025
Details
Estrogen Patches Combined with AR Pathway Inhibitors Show Promise in Prostate Cancer Management - Nicholas James
March 10, 2025
Details
Tumor Suppressor Gene Status Refines Prognosis and Treatment Selection in Metastatic Prostate Cancer - Martino Pedrani
March 8, 2025
Details
Comparing Industry-Sponsored and Investigator-Initiated Trials in Genitourinary Oncology - Srikala Sridhar
March 7, 2025
Details
IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer - Stacy Loeb
March 6, 2025
Details
Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
March 5, 2025
Details
Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor
March 4, 2025
Details
Metastasis-Directed Therapy Improves Outcomes in Oligometastatic Prostate Cancer in WOLVERINE Study - Chad Tang
March 3, 2025
Details
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
March 3, 2025
Details
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
February 27, 2025
Details
Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami
February 27, 2025
Details
REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton
February 27, 2025
Details
Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher
February 27, 2025
Details
Darolutamide Monotherapy in Prostate Cancer: A Phase II Trial Overview - Xin Gao
February 26, 2025
Details
Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris
February 26, 2025
Details
Real-World Treatment Patterns in Advanced Prostate Cancer from PRECISION Data Platform - Oliver Sartor
February 26, 2025
Details
ARASTEP Trial Tests Darolutamide and ADT in High-Risk Biochemically Recurrent Prostate Cancer - Alicia Morgans
February 25, 2025
Details
Talazoparib Improves Survival in HRR-Mutated mCRPC Patients in TALAPRO-2 Trial - Karim Fizazi
February 25, 2025
Details
ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
February 24, 2025
Details
Lineage-Specific EZH2 Activity in Advanced Prostate Cancer Subtypes - Varadha Balaji Venkadakrishnan
February 18, 2025
Details
Intratumoral Heterogeneity Drives Therapy Resistance in Metastatic Prostate Cancer - Laura Sena
February 18, 2025
Details
Canonical Androgen Response Elements in Prostate Cancer Growth Suppression - Christopher Barbieri
February 14, 2025
Details
ADT Remodels the Tumor Microenvironment from Immunologically Cold to Hot - Matthew Dallos
February 10, 2025
Details
ASCL1 and FOXA2 in Neuroendocrine Prostate Cancer - Shaghayegh Nouruzi
February 10, 2025
Details
CDK12 Mutation Types and PARP Treatment Effectiveness - Jonathan Chou
February 7, 2025
Details
PARP Inhibitor Resistance Mechanisms in Prostate Cancer - Johann De Bono
February 5, 2025
Details
Universal Germline Genetic Testing for Prostate Cancer Patients - Neal Shore & Sarah Young
January 30, 2025
Details
Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal
January 28, 2025
Details
AR EcDNA Discovery in Advanced Prostate Cancer Study - George Zhao
January 28, 2025
Details
Machine Learning Stemness Signature for Prostate Cancer - Agustina Sabater & Geraldine Gueron
January 28, 2025
Details
Opevesostat Trial in mCRPC: Targeting Androgen Biosynthesis Upstream for Improved Outcomes - Christian Gratzke
January 27, 2025
Details
ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor
January 24, 2025
Details
Urinary Incontinence in Gay and Bisexual Prostate Cancer Survivors - Kristine Talley
January 23, 2025
Details
Classifying FOXA1 Alterations: Implications for Prostate Cancer Prognosis and Treatment - Emmanuel Antonarakis & Justin Hwang
January 21, 2025
Details
Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal
January 17, 2025
Details
AR Enhancer Amplification and SSTR1 Downregulation in mCRPC - Xiaolin Zhu
January 16, 2025
Details
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs
January 13, 2025
Details
MYC’s Role in Prostate Cancer Immune Suppression and Progression - Mindy Kim Graham
January 13, 2025
Details
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann
January 10, 2025
Details
The Proteogenomics of Prostate Cancer Radioresistance - Roni Haas
January 8, 2025
Details
Study Reveals How Prostate Cancer Alters Bone Structure, Increasing Fracture Risk - Felipe Eltit Guersetti
January 7, 2025
Details
Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist
December 19, 2024
Details
Polyaneuploid Cancer Cells Drive Metastasis and Resist Treatments in Prostate Cancer - Sarah Amend
December 17, 2024
Details
VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery
December 13, 2024
Details
Trial Library Platform Expands Clinical Trial Access for Patients - Hala Borno
December 13, 2024
Details
RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar
December 11, 2024
Details
Response and Progression Criteria for PSMA PET: Imaging Prostate Cancer Outcomes - Wolfgang Fendler
December 9, 2024
Details
Pelvic Muscle Rehabilitation after Radical Prostatectomy - Diane Newman
December 9, 2024
Details
Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman
December 3, 2024
Details
Penile Rehabilitation After Prostate Cancer Treatment - Amy Pearlman
December 3, 2024
Details
Single-Cell Analysis Reveals Heterogeneity in Treatment-Resistant Prostate Cancer - Samir Zaidi
December 2, 2024
Details
Early Palliative Care Boosts Quality of Life for Prostate Cancer Patients - Michael Rabow
December 2, 2024
Details
Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments "Presentation" - Scott Eggener
November 20, 2024
Details
ctDNA Assay Detects AR Enhancer Alterations Linked to Poor Survival - Russell Pachynski, Aadel Chaudhuri & Christopher Maher
November 18, 2024
Details
Which Patients with High-Risk First BCR After Radical Prostatectomy are Candidates for Systemic Therapy Alone Without Local Salvage RT? "Presentation" - Bertrand Tombal
November 15, 2024
Details
In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt
November 15, 2024
Details
Timing of Salvage Radiotherapy in Recurrent Prostate Cancer Management "Discussion"
November 15, 2024
Details
In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis RT? "Presentation" - Paul Nguyen
November 15, 2024
Details
Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients? "Presentation" - Matthew Smith
November 15, 2024
Details
Synchronous Low-Volume mHSPC – in Which Patients Do You Recommend Combination Systemic Therapy plus Local Treatment of the Primary and in Which Patients Is ADT Alone plus RT Enough? "Presentation" - Robert Jones
November 15, 2024
Details
In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor
November 15, 2024
Details
Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James
November 15, 2024
Details
Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas
November 15, 2024
Details
In Which Patients with Metachronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Thomas Zilli
November 15, 2024
Details
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris
November 15, 2024
Details
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
November 15, 2024
Details
Update on the IRONMAN Project "Presentation" - Alicia Morgans
November 15, 2024
Details
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal
November 15, 2024
Details
Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin
November 15, 2024
Details
How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf
November 15, 2024
Details
Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney
November 15, 2024
Details
Management of Frail Patients with mHSPC "Presentation" - Maria De Santis
November 15, 2024
Details
Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard
November 15, 2024
Details
Patient Preferences in Prostate Cancer De-Escalation Strategies "Discussion"
November 15, 2024
Details
Cardiovascular Complications in Advanced Prostate Cancer – How to Prevent Them and How to Monitor Patients? "Presentation" - Thomas Suter
November 15, 2024
Details
How to Select ADT and ARPI Based on CV Risk Profile "Presentation" - Charles Ryan
November 15, 2024
Details
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
November 15, 2024
Details
Gynecomastia – How to Assess and Treat? "Presentation" - Lisa Horvath
November 15, 2024
Details
Hot Flushes – How Can We Help Our Patients? "Presentation" - Anthony Joshua
November 15, 2024
Details
Testosterone Recovery After Stopping ADT – Who Is at Risk for Long-Term Non-Recovery? "Presentation" - Pierre Blanchard
November 15, 2024
Details
Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"
November 15, 2024
Details
Tailoring PARP Inhibitor Therapy for mCRPC Based on Genetic Alterations "Discussion"
November 15, 2024
Details
When to Do Tumour Genomic Profiling in Advanced Prostate Cancer and What? "Presentation" - Niven Mehra
November 15, 2024
Details
Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis
November 15, 2024
Details
Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi
November 15, 2024
Details
Best Use of PARP Inhibitors in mCRPC "Presentation" - Joaquin Mateo
November 15, 2024
Details
PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor? "Presentation" - Johann De Bono
November 15, 2024
Details
How to Manage Side Effects of PARPi? "Presentation" - Elena Castro
November 15, 2024
Details
Managing PSA Recurrence After Prostate Cancer Surgery Treatment "Discussion"
November 15, 2024
Details
PARP Inhibitors in Prostate Cancer Challenges and Opportunities in Clinical Practice "Discussion"
November 15, 2024
Details
Lancet Commission on Prostate Cancer– the Forthcoming Surge in Prostate Cancer Raises Very Different Issues to the Ones We Face Today "Presentation" - Nicholas James
November 15, 2024
Details
How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa? "Presentation" - Onyeanunam Ngozi Ekeke
November 15, 2024
Details
Dealing with Inequality - the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations "Presentation" - Stacy Loeb
November 15, 2024
Details
How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System "Presentation" - Dingwei Ye
November 15, 2024
Details
Global Cancer Care Challenges & Solutions in Developing Nations "Discussion"
November 15, 2024
Details
Notch Signaling Suppresses Neuroendocrine Differentiation in Advanced Prostate Cancer - Sheng-Yu Ku
November 12, 2024
Details
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
November 8, 2024
Details
Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi
November 7, 2024
Details
Comprehensive Atlas Details Prostate Cancer Chromatin Patterns - Raunak Shrestha
November 6, 2024
Details
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter
November 5, 2024
Details
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
November 5, 2024
Details
Olaparib Effective in BRCA2-Altered Biochemical Recurrence Post-Prostatectomy in Phase 2 Study - Catherine Handy Marshall
November 4, 2024
Details
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
November 2, 2024
Details
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
October 30, 2024
Details
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
October 30, 2024
Details
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
October 20, 2024
Details
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
October 15, 2024
Details
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
October 15, 2024
Details
AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial - Bram De Laere
October 14, 2024
Details
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
October 12, 2024
Details
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
October 9, 2024
Details
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
October 7, 2024
Details
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
October 7, 2024
Details
STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly
October 3, 2024
Details
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran
October 3, 2024
Details
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
October 2, 2024
Details
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
October 1, 2024
Details
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
October 1, 2024
Details
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
October 1, 2024
Details
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
September 30, 2024
Details
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
September 30, 2024
Details
PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
September 28, 2024
Details
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
September 27, 2024
Details
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
September 26, 2024
Details
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
September 26, 2024
Details
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross
September 24, 2024
Details
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
September 24, 2024
Details
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
September 24, 2024
Details
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
September 23, 2024
Details
T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal
September 22, 2024
Details
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
September 20, 2024
Details
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
September 19, 2024
Details
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
September 18, 2024
Details
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
September 16, 2024
Details
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
September 15, 2024
Details
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
September 15, 2024
Details
2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen
September 6, 2024
Details
Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs - Daniel Joyce
August 28, 2024
Details
STORM Trial Examines Elective Nodal Radiotherapy in Treating Prostate Cancer Recurrence - Piet Ost
August 24, 2024
Details
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
August 23, 2024
Details
RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso
August 21, 2024
Details
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
August 9, 2024
Details
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
August 6, 2024
Details
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
August 5, 2024
Details
PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan
August 1, 2024
Details
PSMA-PET/CT Guided Salvage Radiotherapy: Improving Prostate Cancer Outcomes - Constantinos Zamboglou
August 1, 2024
Details
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor
July 31, 2024
Details
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz
July 31, 2024
Details
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
July 30, 2024
Details
Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni
July 30, 2024
Details
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
July 29, 2024
Details
2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
July 26, 2024
Details
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
July 25, 2024
Details
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
July 22, 2024
Details
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
July 2, 2024
Details
Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner
June 30, 2024
Details
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
June 28, 2024
Details
PROSTATE-IQ Trial: Reducing ADT Burden in Salvage Radiotherapy - Karen Hoffman
June 27, 2024
Details
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
June 25, 2024
Details
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson
June 24, 2024
Details
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
June 22, 2024
Details
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
June 22, 2024
Details
Prostate Cancer Diversity Revealed: AR and Neuroendocrine Signatures - Yu-Wei Chen
June 21, 2024
Details
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
June 21, 2024
Details
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
June 20, 2024
Details
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
June 18, 2024
Details
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
June 18, 2024
Details
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
June 17, 2024
Details
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
June 17, 2024
Details
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
June 13, 2024
Details
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
June 13, 2024
Details
Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon
June 13, 2024
Details
Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle
June 12, 2024
Details
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
June 12, 2024
Details
ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak
June 11, 2024
Details
CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos
June 11, 2024
Details
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
June 11, 2024
Details
PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler
June 11, 2024
Details
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
June 11, 2024
Details
Predicting Response to Bipolar Androgen Therapy: A Blood-Based Biomarker Approach - Samuel Denmeade
June 10, 2024
Details
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo
June 10, 2024
Details
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
June 10, 2024
Details
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
June 4, 2024
Details
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
May 31, 2024
Details
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
May 29, 2024
Details
Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala
May 28, 2024
Details
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
May 28, 2024
Details
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
May 28, 2024
Details
EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore
May 28, 2024
Details
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
May 28, 2024
Details
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore
May 27, 2024
Details
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
May 24, 2024
Details
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
May 24, 2024
Details
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
May 24, 2024
Details
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
May 23, 2024
Details
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor
May 23, 2024
Details
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
May 23, 2024
Details
The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal
May 22, 2024
Details
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
May 22, 2024
Details
Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 in Prostate Cancer - Jelani Zarif
May 21, 2024
Details
Non-Invasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation - Himisha Beltran & Francesca Demichelis
May 15, 2024
Details
Evidence-Based Guidelines Update Salvage Radiation Protocols - Todd Morgan
May 14, 2024
Details
Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke
May 14, 2024
Details
PEACE V (STORM) Trial: Comparing MDT vs. Elective Nodal Irradiation for Oligorecurrent Prostate Cancer - Thomas Zilli
May 6, 2024
Details
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
April 23, 2024
Details
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
April 22, 2024
Details
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
April 18, 2024
Details
A US Real-World Study of Treatment Patterns and Outcomes in Localized or Locally Advanced Prostate Cancer Patients - Beyond the Abstract
April 15, 2024
Details
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
April 15, 2024
Details
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
April 12, 2024
Details
PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid
April 9, 2024
Details
Examining the 340B Program's Role in Mitigating Disparities in Prostate Cancer Treatment - Kassem Faraj
April 4, 2024
Details
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
March 5, 2024
Details
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
March 1, 2024
Details
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore
February 28, 2024
Details
Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova
February 27, 2024
Details
Biochemical Recurrence in Patients with Prostate Cancer after Primary Definitive Therapy: Next-Generation Imaging and Treatment Based on Risk Stratification - Beyond the Abstract
February 27, 2024
Details
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
February 27, 2024
Details
PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik
February 27, 2024
Details
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
February 21, 2024
Details
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
February 7, 2024
Details
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
February 6, 2024
Details
Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt
January 30, 2024
Details
Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda
January 22, 2024
Details
ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg
January 4, 2024
Details
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract
January 2, 2024
Details
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
December 15, 2023
Details
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract
December 12, 2023
Details
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
December 12, 2023
Details
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
November 29, 2023
Details
ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett
November 20, 2023
Details
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard
November 17, 2023
Details
Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
November 17, 2023
Details
Shifting Clinical Trial Design Towards Improving Patient Enrollment - Michael Morris
November 17, 2023
Details
AMG 509's Potential in Prostate Cancer Therapy - Michael Morris
November 17, 2023
Details
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
November 17, 2023
Details
Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George
November 16, 2023
Details
Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay
November 15, 2023
Details
The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor
November 10, 2023
Details
Clinical Implications and Patient Care: The SNMMI Consensus on Lutetium PSMA 617 Therapy for Advanced Prostate Cancer - Heather Jacene & Oliver Sartor
November 2, 2023
Details
Influencing Best Practices for Genomic and Germline Testing in Urology - Abhishek Srivastava
October 6, 2023
Details
Comprehensive Genomic Profiling and Treatment Patterns Across Ancestries in Advanced Prostate Cancer - Brandon Mahal
August 17, 2023
Details
The REASSURE Trial: Long-Term Safety of Radium-223 in Advanced Prostate Cancer - Oliver Sartor
July 31, 2023
Details
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer - David Quigley
July 24, 2023
Details
The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein
July 13, 2023
Details
DDR and PARP Inhibition: What's the Damage? - David VanderWeele
July 10, 2023
Details
Prospective Monitoring of Biochemical Recurrence with PSMA PET - Ravi Madan
July 10, 2023
Details
Understanding the Potential and Challenges of Sipuleucel-T and Radium-223 in the Management of Metastatic Castration-Resistant Prostate Cancer - Sumit Subudhi
July 7, 2023
Details
PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik
July 3, 2023
Details
Analyzing Quality of Life and Survival from CHAARTED Prostate Cancer Trial - Daniel Sentana Lledo
July 3, 2023
Details
Primary Analysis of STARTAR: A Phase 2 Salvage Trial for High-Risk Prostate Cancer with Biochemical Recurrence - Tian Zhang
July 3, 2023
Details
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
June 23, 2023
Details
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury
June 22, 2023
Details
Early Aggressive Treatment Shows Promise for Prostate Cancer Recurrence - Stephen J. Freedland
June 22, 2023
Details
Understanding BRCA Mutations: The Pivotal Impact of the CAPTURE Study - David Olmos
June 22, 2023
Details
The Added Value of Docetaxel in Combination with ADT and ARPI for the Treatment of mHSPC - Ursula Vogl
June 21, 2023
Details
Navigating Salvage Radiotherapy with Insights from PSMA PET - Jeremie Calais
June 21, 2023
Details
Predictive Modeling for 177Lu-PSMA-617 Therapy in Patients with mCRPC - Ken Herrmann
June 21, 2023
Details
Unlocking Prostate Cancer Treatment: The Pathway of CAR T Targeting Prostate Stem Cell Antigen - Tanya Dorff
June 21, 2023
Details
Integration of Lutetium into Clinical Practice: A Urologist's Perspective - Neal Shore
June 20, 2023
Details
Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg
June 16, 2023
Details
Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen
June 14, 2023
Details
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
June 14, 2023
Details
Combating Prostate Cancer: The Role of the NRG-GU-011 Study in Transforming Treatments - Bridget Koontz
June 13, 2023
Details
TALAPRO-2 Study Reveals Efficacy and Tolerability of Talazoparib Combination for Prostate Cancer - Neeraj Agarwal
June 13, 2023
Details
Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith
June 13, 2023
Details
Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi
June 13, 2023
Details
Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay
June 13, 2023
Details
Unlocking Prostate Cancer Therapeutics: The Potential of Minor Spliceosome Inhibition - Mark Rubin
June 11, 2023
Details
Investigating the Role and Therapeutic Potential of B7-H3 in Prostate Cancer - Christina Guo
June 9, 2023
Details
Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies - Di Zhao
June 5, 2023
Details
Combination Treatment in Metastatic Prostate Cancer: Is the Bar Too High or Have We Fallen Short? - Kenneth Chen
May 24, 2023
Details
PSMA Expression in Advanced Prostate Cancer: Implications for Targeted Therapies -Himisha Beltran
May 19, 2023
Details
Insights into Global Treatment Patterns for Advanced Prostate Cancer: The IRONMAN Registry - Lorelei Mucci &. Dan George
May 9, 2023
Details
Exploring PSMA Expression Variations in Metastatic Prostate Cancer: The Role of Reversible Epigenetic Changes - Michael Haffner
May 9, 2023
Details
EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore
May 2, 2023
Details
Improving Genetic Testing Rates in Advanced Prostate Cancer - Pedro Barata
March 14, 2023
Details
DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal
March 6, 2023
Details
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
March 3, 2023
Details
Treating Biochemical Recurrence With Enhanced Therapy Added to Standard of Care and Targeted Radiation Using PET Imaging, ECOG-ACRIN EA8191 (INDICATE) - Neha Vapiwala
February 24, 2023
Details
NCCN Guidelines: A Framework for PET Imaging Integration in Prostate Cancer Care - Edward Schaeffer
February 1, 2023
Details
SPARE Trial's Implications for Prostate Cancer Patients - Carsten-Henning Ohlmann
January 31, 2023
Details
Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management - Neeraj Agarwal
January 31, 2023
Details
Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran
January 25, 2023
Details
Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross
January 10, 2023
Details
Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer - Saul Priceman
January 10, 2023
Details
The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes - Philip Sutera
January 3, 2023
Details
Geographic Variation in the Use of Doublet Therapy for Metastatic Prostate Cancer - Samuel Washington
December 19, 2022
Details
Exploring the Molecular Mechanisms of Tumor Progression in Metastatic Prostate Cancer among Men of African Ancestry (MET-PAAM) - Clayton Yates
December 19, 2022
Details
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
December 5, 2022
Details
Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang
November 30, 2022
Details
Contact-02: A Phase III Trial Shaping the Future of Metastatic Prostate Cancer Care - Neeraj Agarwal
November 22, 2022
Details
Exploring the New Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
November 22, 2022
Details
The AFT-19 Study: A Comprehensive Look at High-Risk Prostate Cancer Treatment - Rahul Aggarwal
November 17, 2022
Details
The Promising Path of PSMA PET Imaging and Lutetium-177-PSMA in GU Oncology and Prostate Cancer Treatment - Susan Slovin
November 9, 2022
Details
Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor
November 2, 2022
Details
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
November 1, 2022
Details
CAR T and Cellular-Based Therapies - Vivek Narayan
October 17, 2022
Details
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
October 16, 2022
Details
Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang
October 16, 2022
Details
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
October 16, 2022
Details
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
October 16, 2022
Details
Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda Giri
October 16, 2022
Details
Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis
October 16, 2022
Details
Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller
October 13, 2022
Details
When and How Much: A Deep Dive into the RADICALS Trial's Questions on Radiotherapy and Hormone Therapy - Nicholas James
October 11, 2022
Details
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
October 3, 2022
Details
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
September 27, 2022
Details
What Is the Evidence of Systemic Therapies (Alone or in Combination With MDT) in Oligometastatic mHSPC? APCCC 2022 Presentation - Mary Ellen Taplin
September 21, 2022
Details
Impact of Histology Variants (Ductal/Intraductal/Cribriform) on Treatment Recommendation Presentation - Declan Murphy
September 21, 2022
Details
Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner
September 21, 2022
Details
Update on Immune Checkpoint Inhibitors APCCC 2022 Presentation - Emmanuel Antonarakis
September 21, 2022
Details
Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment APCCC 2022 Presentation - Eric Small
September 18, 2022
Details
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Muscle Strength? APCCC 2022 Presentation - Heather Cheng
September 15, 2022
Details
Smarter Screening In Prostate Cancer - Sigrid Carlsson
August 31, 2022
Details
Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin
August 28, 2022
Details
Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova
August 7, 2022
Details
How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi
August 7, 2022
Details
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
August 2, 2022
Details
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
July 25, 2022
Details
The Efficacy and Safety of Relugolix versus Leuprolide in the HERO Study in Men with Advanced Prostate Cancer Based on Baseline BMI - Fred Saad
July 25, 2022
Details
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
July 25, 2022
Details
Patient-Centric Approaches: The Urgent Need for Genetic Testing in Prostate Cancer - Brittany Szymaniak
June 23, 2022
Details
Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone
June 23, 2022
Details
Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone
June 22, 2022
Details
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
June 8, 2022
Details
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
May 24, 2022
Details
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
May 11, 2022
Details
Lessons Learned in the STAMPEDE Trial - Nicholas James
April 30, 2022
Details
Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
April 22, 2022
Details
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
April 14, 2022
Details
Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner
April 14, 2022
Details
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
April 7, 2022
Details
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
April 3, 2022
Details
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell
March 16, 2022
Details
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
February 24, 2022
Details
From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom
January 23, 2022
Details
Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke
January 11, 2022
Details
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
November 2, 2021
Details
A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone
October 31, 2021
Details
COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal
October 4, 2021
Details
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
August 27, 2021
Details
HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane
August 13, 2021
Details
Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal
July 30, 2021
Details
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
June 22, 2021
Details
Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming
June 9, 2021
Details
Relugolix in the Treatment of Advanced Prostate Cancer- Neeraj Agarwal
May 28, 2021
Details
Transitioning Patients to an Oral GnRH Antagonist and Optimizing Patient Outcomes - Brenda Martone
April 16, 2021
Details
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
March 29, 2021
Details
Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley
March 25, 2021
Details
Stereotactic Ablative Body Radiotherapy in Patients in Oligometastatic Cancers: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
February 4, 2021
Details
First and Only Oral GnRH Receptor Antagonist Orgovyx for the Treatment of Advanced Prostate Cancer - Charles Ryan & Alicia Morgans
December 18, 2020
Details
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi
July 3, 2020
Details
PROSPER Trial: Significant Improvement in Metastasis-Free Survival (MFS) and Overall Survival (OS) Demonstrated Nonmetastatic Castration-Resistant Prostate Cancer Patients - Fred Saad
July 3, 2020
Details
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
June 7, 2020
Details
Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland
April 18, 2020
Details
The Statisticians Perspective on Methods of Comparing Prostate Cancer Clinical Trial Data - Matthew Sydes
April 11, 2020
Details
AR Indifferent Subtype Tumors in Prostate Cancer - Ana Aparicio
March 4, 2020
Details
Supportive Therapy in Androgen Deprivation (STAND) - Rahul Aggarwal
March 1, 2020
Details
Testosterone Replacement in the Treatment of Advanced Prostate Cancer - Sam Denmeade and Michael Schweizer
January 7, 2020
Details
Recurrent Disease After Radiation Therapy, the Role of the Radiation Oncologist - Felix Feng and Piet Ost
September 16, 2019
Details
An Update on the PRONOUNCE Trial, Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease - Susan Slovin
January 15, 2020
Details
Advanced Prostate Cancer Clinic: What’s Changing? - Maha Hussain
December 18, 2019
Details
Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis
December 7, 2019
Details
Management of Advanced Prostate Cancer in the Middle East - Deborah Mukherji
December 6, 2019
Details
Aggressive Variant Prostate Cancer: Identifying Patients with Specific Molecular Signature - Ana Aparicio
December 4, 2019
Details
Precision Oncology Program for Cancer of the Prostate (POPCaP) - Matthew Rettig
July 27, 2020
Details
Interpreting Phase III Clinical Trial Data - Susan Halabi
November 24, 2019
Details
The Changing Landscape for Locally Advanced Prostate Cancer- Maria de Santis
November 11, 2019
Details
Disparities and Outcomes in Men with Prostate Cancer - Susan Halabi, Mindy Hebert-DeRouen, and Daniel George
November 11, 2019
Details
The IRONMAN - An International Registry for Men with Advanced Prostate Cancer - Dana Rathkopf
November 8, 2019
Details
Advancing Prostate Cancer Research - The Prostate Cancer Clinical Trials Consortium (PCCTC) - Sarah Wise
October 31, 2019
Details
Definitions and Concepts of Oligometastatic Prostate Cancer - Interview with Robert Reiter
October 27, 2019
Details
Managing the Complications of Androgen Deprivation Therapy - Mark Frydenberg
October 15, 2019
Details
Imaging Modalities to Treat Node-Positive Disease - Interview with Declan Murphy
October 3, 2019
Details
How to Treat Men with pN1 Prostate Cancer - Presentation - Alberto Bossi
October 2, 2019
Details
Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging Presentation - Ian Davis
October 1, 2019
Details
Radiation Therapy Options for Men with Clinically Node-Positive Prostate Cancer - Mack Roach
September 26, 2019
Details
The Future of Biomarkers in Advanced Prostate Cancer - Mark Rubin
September 26, 2019
Details
Radiation Therapy Options for Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Mack Roach
September 25, 2019
Details
How Best to Treat cN1 Prostate Cancer - Karim Fizazi
September 25, 2019
Details
Ethnicity and Prognosis of Prostate Cancer - Christopher Logothetis
September 25, 2019
Details
Testosterone Measurement – Which Test and When? - Martin Gleave
September 25, 2019
Details
The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan
September 24, 2019
Details
The Management of Hot Flushes in Advanced Prostate Cancer - Mark Frydenberg
September 24, 2019
Details
The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort
September 24, 2019
Details
A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi
September 24, 2019
Details
The Future of Advanced Prostate Cancer Management: In Locally Advanced Prostate Cancer Presentation - Alberto Briganti
September 24, 2019
Details
The Best Use of Antiresorptive Therapy in CRPC Presentation - Matthew Smith
September 24, 2019
Details
The Management of Fatigue, Cognition, and Dementia in Prostate Cancer Patients Presentation - Charles Ryan
September 22, 2019
Details
Management of ADT Metabolic Complications: Assessment, Monitoring, Interventions Presentation - Neal Shore
September 22, 2019
Details
The Future of Advanced Prostate Cancer Management: Access to Treatments Presentation - Karim Fizazi
September 18, 2019
Details
The Future of Advanced Prostate Management Presentation - Mark Rubin
September 18, 2019
Details
The Future of APC Management in Polymetastatic Disease Presentation - William Oh
September 18, 2019
Details
The Neuroendocrine Prostate Cancer Spectrum Diagnosis and Treatment Presentation - Eleni Efstathiou
September 17, 2019
Details
Which Systemic Therapy for Which Patient with Newly Diagnosed Metastatic Prostate Cancer Presentation - Chris Sweeney
September 17, 2019
Details
Sinai Researchers Find First Mechanistic Link between World Trade Center Dust & Prostate Cancer - William Oh
September 10, 2019
Details
Looking Into the Future: Oligometastatic Disease Presentation - Misha Beltran
September 6, 2019
Details
Movember Session: Outcomes Research – IRONMAN Project - Alicia Morgans and Ian Davis
September 5, 2019
Details
How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer: Surgery Options Presentation - Declan Murphy
September 4, 2019
Details
How to Treat Men With Newly Diagnosed cN1 cM0 Prostate Cancer - Systemic Therapy Options - Nicholas James
October 30, 2019
Details
Management of Men With PSA Recurrence or Persistence After Prostatectomy: Presentation - Christopher Evans
September 4, 2019
Details
Management of Men with PSA Recurrence After Radical Local Radiation Therapy Presentation - Felix Feng
September 4, 2019
Details
Disparities in Prostate Cancer Management in the United States Presentation - Alicia Morgans
September 4, 2019
Details
Pharmaco-ethnicity and Its Impact on Treatment Presentation - Darren MC Poon
September 4, 2019
Details
APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study - Charles Ryan
September 4, 2019
Details
Clinical Utility of Molecular Biomarkers Presentation - Johann de Bono
September 3, 2019
Details
Baseline PSA Level in Midlife and Aggressive Prostate Cancer in African American Men - Mark Preston
August 21, 2019
Details
Optimizing Care in Localized Prostate Cancer - Mary-Ellen Taplin and Adam Kibel
August 20, 2019
Details
Latin American Oncology Group (LACOG), a Cooperative Group Consensus - Fernando Maluf
August 14, 2019
Details
Credentialing Imaging as an Outcome Measure in Prostate Cancer - Lawrence H. Schwartz and Michael J. Morris
August 15, 2019
Details
Radiation Therapy Options for Prostate Cancer - Paul Nguyen
August 13, 2019
Details
Ben Maughan Highlights Key Practice Changing Prostate Cancer Data
July 31, 2019
Details
Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt
May 31, 2019
Details
Cognitive Function in Men with Prostate Cancer - Claire Pernar
August 3, 2019
Details
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor
May 21, 2019
Details
Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney
May 24, 2019
Details
Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Daniel Spratt
May 21, 2019
Details
Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery
April 1, 2019
Details
Urologists Perspectives on Prostate Cancer Presentations from ASCO GU 2019 - Edward Schaeffer
March 26, 2019
Details
Practice Patterns of Active Surveillance in Prostate Cancer - Matt Cooperberg
March 14, 2019
Details
Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar
March 15, 2019
Details
Results from Recent Pivotal Trials in Prostate Cancer - Cora Sternberg
February 28, 2019
Details
Prostate Cancer Disparities in the VA Health System - Megan McNamara
February 23, 2019
Details
A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer - Tom Keane
February 21, 2019
Details
Optimizing ADT in Prostate Cancer Patients - Tom Keane
February 18, 2019
Details
3D Prostate Gland Uptake of 18F Choline PET CT - Association with Overall Survival in Patients with Hormone-naive Prostate Cancer - May Sadik
February 5, 2019
Details
Neoadjuvant Therapy Prior to Prostatectomy - Mary-Ellen Taplin
January 30, 2019
Details
Life-Prolonging Treatments for Advanced Prostate Cancer - Maha Hussain
January 30, 2019
Details
Disparities in Prostate Cancer Clinical Trial Participation - Hala Borno
January 29, 2019
Details
18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser
January 28, 2019
Details
68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias
January 28, 2019
Details
A Review of Imaging Modalities in Prostate Cancer - Peter Pinto
December 2, 2018
Details
Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane
November 30, 2018
Details
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
November 29, 2018
Details
Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran
November 7, 2018
Details
Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James
November 4, 2018
Details
ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess
November 1, 2018
Details
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad
August 7, 2019
Details
Genetic Screening for Patients with Prostate Cancer - Todd Morgan
September 30, 2018
Details
IRONMAN Registry: A Global Landmark Trial in Advanced Prostate Cancer
September 19, 2018
Details
Current State of Liquid Biopsies in Prostate Cancer - Gert Attard
August 20, 2018
Details
Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro
August 14, 2018
Details
The United States Preventive Services Task Force PSA Screening Recommendations- David Penson
July 31, 2018
Details
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
July 25, 2018
Details
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
June 27, 2018
Details
Optimizing Care in Patients with High Risk Prostate Cancer - Interview with Edward Schaeffer
June 14, 2018
Details
Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb
June 14, 2018
Details
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
June 12, 2018
Details
Clinical Implications of the Abi Race Study: Interview with Dan George
June 5, 2018
Details
The RADICAL PC Project - Jehonathan Pinthus
April 11, 2018
Details
New Concepts in ADT- Thomas Keane
April 8, 2018
Details
Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans
March 31, 2018
Details
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin
February 23, 2018
Details